CD7 and acute lymphoblastic leukemia: However, the use of chimeric antigen receptor (CAR) T cell therapy targeting CD7 as a novel immunotherapy for the treatment of (r/r) T-ALL faces major challenges and is in the early stages (10, 11).CAR-T therapy is a transitional treatment for patients with r/r ALL, but the therapeutic effects last only for 3 months to 1 year (12).